Non-linear MHD modelling of transients in tokamaks: a review of recent advances with the JOREK code

Autor: M. Hoelzl, G.T.A. Huijsmans, F.J. Artola, E. Nardon, M. Becoulet, N. Schwarz, A. Cathey, S.J.P. Pamela, K. Aleynikova, F. Antlitz, V. Bandaru, H. Bergström, A. Bhole, T. Bogaarts, D. Bonfiglio, F. Cipolletta, T. Driessen, L. Edes, S. Futatani, G. Hao, F. Hindenlang, I. Holod, D. Hu, S. Hu, N. Isernia, H. Isliker, S.K. Kim, M. Kong, S. Korving, L. Kos, I. Krebs, S.J. Lee, Y.C. Liang, Z. Liang, S.J. Liu, Z.X. Lu, L. Meier, L. Messfeldt, V. Mitterauer, N. Nikulsin, B. Nkonga, R. Ramasamy, J. Reinking, C. Rogge, G. Rubinacci, K. Särkimäki, T. Smits, C. Sommariva, R. Sparago, K. Strien, M. Szucs, W. Tang, J. van Tongeren, F. Vannini, S. Ventre, F. Villone, C. Wang, L. Wang, F. Wieschollek, F. Wouters, J. Zielinski, H. Zhang

Publikováno v: Nuclear Fusion, Vol 64, Iss 11, p 112016 (2024)

Transient magneto-hydrodynamic (MHD) events like edge localized modes (ELMs) or disruptions are a concern for magnetic confinement fusion power plants. Research with the MHD code JOREK towards understanding control of such instabilities is reviewed h

Externí odkaz: https://doaj.org/article/f277d699848d4be4afa02e265faf2702

Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy

Autor: Fenna M. Jansen, Lisa J. T. Smits, Pepijn W. A. Thomas, Dirk J. de Jong, Joany E. Kreijne, Willemijn A. van Dop, Nathan den Broeder, Frank Hoentjen

Publikováno v: Jansen, F M, Smits, L J T, Thomas, P W A, de Jong, D J, Kreijne, J E, van Dop, W A, den Broeder, N & Hoentjen, F 2023, ' Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy ', Digestive Diseases and Sciences, vol. 68, no. 7, pp. 2936-2945 . https://doi.org/10.1007/s10620-023-07950-0
Digestive Diseases and Sciences, 68, 7, pp. 2936-2945
Digestive Diseases and Sciences. Springer New York

Contains fulltext : 294343.pdf (Publisher’s version ) (Open Access) BACKGROUND: Outpatient visits and laboratory assessments are routinely scheduled every 3 to 4 months in thiopurine-treated patients with inflammatory bowel disease (IBD) to timely

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2fcf105b2c9522d32ae27ea1439760
https://research.vumc.nl/en/publications/08b520d7-daa6-452a-9978-4d28d3c837c0

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) a pragmatic, open-label, non-inferiority, randomised controlled trial

Autor: Reinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, Lisa J T Smits, Femke Atsma, Wietske Kievit, Dirk J de Jong, Annemarie C de Vries, Paul J Boekema, Rachel L West, Alexander G L Bodelier, Ingrid A M Gisbertz, Frank H J Wolfhagen, Tessa E H Römkens, Maurice W M D Lutgens, Adriaan A van Bodegraven, Bas Oldenburg, Marieke J Pierik, Maurice G V M Russel, Nanne K de Boer, Rosalie C Mallant-Hent, Pieter C J ter Borg, Andrea E van der Meulen-de Jong, Jeroen M Jansen, Sita V Jansen, Adrianus C I T L Tan, C Janneke van der Woude, Frank Hoentjen, Desirée van Noord, Jildou Hoekstra, Johannes T. Kamphuis, Moniek H.P. Gorter, Aura A.J. van Esch

Publikováno v: Lancet Gastroenterology & Hepatology, 8, 4, pp. 343-355
Lancet Gastroenterology & Hepatology, 8, 343-355
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd
LADI study group and the Dutch Initiative on Crohn and Colitis 2023, ' Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) : a pragmatic, open-label, non-inferiority, randomised controlled trial ', The Lancet Gastroenterology and Hepatology, vol. 8, no. 4, pp. 343-355 . https://doi.org/10.1016/S2468-1253(22)00434-4
The Lancet Gastroenterology and Hepatology, 8(4), 343-355. Elsevier Ltd.

Item does not contain fulltext BACKGROUND: Despite its effectiveness in treating Crohn's disease, adalimumab is associated with an increased risk of infections and high health-care costs. We aimed to assess clinical outcomes of increased adalimumab d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d4a13f67ca392c8811058105e50cf3a
https://repository.ubn.ru.nl/handle/2066/293716

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.